Advertisement

International Journal of Clinical Oncology

, Volume 23, Issue 6, pp 1121–1126 | Cite as

Definitive chemoradiotherapy for anal canal cancer: single-center experience

  • Izumi TachibanaEmail author
  • Yasumasa Nishimura
  • Masahiro Inada
  • Kohei Fukuda
  • Kazuki Ishikawa
  • Tatsuyuki Nishikawa
  • Masaki Yokokawa
  • Kiyoshi Nakamatsu
  • Shuichi Kanamori
  • Jin-ichi Hida
Original Article
  • 127 Downloads

Abstract

Background

Chemoradiotherapy (CRT) is a standard treatment for anal canal cancer although many patients with anal canal cancer undergo surgery in Japan. The efficacy of CRT for anal canal cancer was evaluated retrospectively.

Methods

Medical charts of 13 patients with anal canal cancer treated by definitive CRT from October 2004 to May 2016 were reviewed. Twelve patients had squamous cell carcinoma and one had adeno-squamous carcinoma. PET/CT simulation was performed in nine patients. The median total dose was 59.4 Gy (range 57.6–63.4 Gy) with fractions of 1.8–2.0 Gy. Ten patients received chemotherapy with mitomycin C (10 mg/m2) and fluorouracil (5-FU) (800 mg/m2 over 4 days) in weeks 1 and 5, while two patients were treated with cisplatin (40 mg) and 5-FU (750 mg over 5 days) in weeks 1 and 5. One elderly patient received radiotherapy (RT) alone.

Results

All 13 patients were alive after a median follow-up period of 102 months (range 16–121 months). Local failure only occurred in the patient with adeno-squamous cell carcinoma, while there was no loco-regional recurrence or distant metastasis in the other 12 patients. The 5-year loco-regional control rate (LRC) and 5-year overall survival rate (OS) were 92% and 100%, respectively. Acute toxicities of ≥ grade 3 were observed in six patients (46%), mainly being dermatitis around the anal verge, and late toxicity of ≥ grade 3 occurred in one patient.

Conclusion

CRT for squamous cell carcinoma of the anal canal achieved good LRC and OS with acceptable toxicities.

Keywords

Anal canal cancer Chemoradiotherapy Intensity-modulated radiation therapy Squamous cell carcinoma 

Notes

Acknowledgements

This study was partly supported by the National Cancer Center Research and Development Fund (Grant no. 29-A-3).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Nigro ND, Vaitkevicius VK, Considine B Jr (1974) Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 17(3):354–356CrossRefGoogle Scholar
  2. 2.
    UKCCCR Anal Cancer Trial Working Party (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 19(9034):1049–1054 348(Google Scholar
  3. 3.
    Bartelink H, Roelofsen F, Eschwege F et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15(5):2040–2049CrossRefGoogle Scholar
  4. 4.
    Gunderson LL, Winter KA, Ajani JA et al (2012) Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 30(35):4344–4351CrossRefGoogle Scholar
  5. 5.
    Takashima A, Shimada Y, Hamaguchi T et al (2009) Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol 14(5):416–420CrossRefGoogle Scholar
  6. 6.
    Okubo M, Nishimura Y, Nakamatsu K et al (2010) Radiation treatment planning using positron emission and computed tomography for lung and pharyngeal cancers: a multiple-threshold method for [(18)F] fluoro-2-deoxyglucose activity. Int J Radiat Oncol Biol Phys 77(2):350–356CrossRefGoogle Scholar
  7. 7.
    Myerson RJ, Garofalo MC, El Naqa I et al (2008) Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 74(3):824–830CrossRefGoogle Scholar
  8. 8.
    Ng M, Leong T, Chander S et al (2012) Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys 83(5):1455–1462CrossRefGoogle Scholar
  9. 9.
    Flam M, John M, Pajak TF et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14(9):2527–2539CrossRefGoogle Scholar
  10. 10.
    Okamoto M, karasawa K, Ito Y et al (2006) Radiotherapy for anal canal cancer in Japan: a retrospective multi-institutional study. Int J Radiat Oncol Biol Phys 66(3):s311–s312CrossRefGoogle Scholar
  11. 11.
    Japanese Society for Therapeutic Radiology and Oncology (2016) The guideline for radiotherapy planning. Kanehara Shuppan, Tokyo (in Japanese) Google Scholar
  12. 12.
    Lépinoy A, Lescut N, Puyraveau M et al (2015) Evaluation of a 36 Gy elective node irradiation dose in anal cancer. Radiother Oncol 116(2):197–201CrossRefGoogle Scholar
  13. 13.
    NCCN Guidelines Version 2.2017 Anal Carcinoma. http://www.tri-kobe.org/nccn/guideline/colorectal/english/anal.pdf. Accessed 21 Feb 2018
  14. 14.
    Boman BM, Moertel CG, O’Connell MJ et al (1984) Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 54(1):114–125CrossRefGoogle Scholar
  15. 15.
    Sameshima S, Sawada T, Nagasako K (2005) Squamous cell carcinoma of anus and carcinoma in association with anal fistula in Japan, multi-institutional registration (in Japanese). J Jpn Soc Coloproctol 58(8):415–421CrossRefGoogle Scholar
  16. 16.
    Hannes S, Reinisch A, Bechstein WO et al (2016) Salvage abdominoperineal excisions in recurrent anal cancer–impact of different reconstruction techniques on outcome, morbidity, and complication rates. Int J Colorectal Dis 31(3):653–659CrossRefGoogle Scholar
  17. 17.
    Pesi B, Scaringi S, Di Martino C et al (2017) Results of surgical salvage treatment for anal canal cancer: a retrospective analysis with overview of the literature. Dig Surg 34(5):380–386CrossRefGoogle Scholar
  18. 18.
    Clivio A, Fogliata A, Franzetti-Pellanda A et al (2009) Volumetric-modulated arc radiotherapy for carcinomas of the anal canal: a treatment planning comparison with fixed field IMRT. Radiother Oncol 92(1):118–124CrossRefGoogle Scholar
  19. 19.
    Noffsinger A, Witte D, Cecilia M et al (1992) The relationship of human papilloma viruses to anorectal neoplasia. Cancer 70:1276–1286CrossRefGoogle Scholar
  20. 20.
    Fallai C, Cerrotta A, Valvo F et al (2007) Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol 61(3):261–268CrossRefGoogle Scholar
  21. 21.
    Rousseau DL Jr, Thomas CR Jr, Petrelli NJ et al (2005) Squamous cell carcinoma of the anal canal. Surg Oncol 14(3):121–132CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2018

Authors and Affiliations

  • Izumi Tachibana
    • 1
    Email author
  • Yasumasa Nishimura
    • 1
  • Masahiro Inada
    • 1
  • Kohei Fukuda
    • 1
  • Kazuki Ishikawa
    • 1
  • Tatsuyuki Nishikawa
    • 2
  • Masaki Yokokawa
    • 3
  • Kiyoshi Nakamatsu
    • 1
  • Shuichi Kanamori
    • 1
  • Jin-ichi Hida
    • 4
  1. 1.Department of Radiation OncologyKindai University of MedicineOsaka-SayamaJapan
  2. 2.Department of RadiologyUjitakeda HospitalUjiJapan
  3. 3.Department of Radiation OncologyYamato Takada Municipal HospitalYamato-takadaJapan
  4. 4.Department of SurgeryKindai University of MedicineOsaka-SayamaJapan

Personalised recommendations